Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat-containing protein 58 (LRRC58) is a protein encoded by the LRRC58 gene in humans and is characterized by the presence of leucine-rich repeats, structural motifs known to mediate protein-protein interactions[6][14]. Recent research indicates that LRRC58 functions as a substrate adaptor within an E3 ubiquitin ligase complex, facilitating the proteasomal degradation of cysteine dioxygenase type 1 (CDO1)—a key enzyme in cysteine metabolism—thus implicating LRRC58 in the regulation of cysteine catabolism and cellular protein homeostasis[1]. Although LRRC58 is predicted to be involved in intracellular signal transduction and various metabolic regulatory processes, there is currently no evidence designating it as a classic therapeutic target (such as receptor, enzyme, transporter, or ion channel) and no established role in major human disease pathogenesis or clinical therapy[5][13][14].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine-rich repeat-containing protein 58 (LRRC58).